POSTER SESSION B
Thursday, June 21
12:45 p.m.-3:30 p.m.
Soprano Foyer

B01  Regulation of cellular dormancy in disseminated breast cancer cells. Ana Grujovic. University of Regensburg, Regensburg, Germany.

B02  Differential gene expression profiles of disseminated cancer cells derived from the bone marrow of luminal A and B breast cancer patients at minimal residual disease. Christoph Irlbeck. University of Regensburg, Regensburg, Germany.

B03  The earliest precursor cell of melanoma metastasis: Identification and molecular characterization of candidate metastasis founders. Courtney König. University of Regensburg, Regensburg, Germany.

B04  Role of histone variants in regulating dormancy and senescence programs in cancer cells. Dan Sun. Icahn School of Medicine at Mount Sinai, New York, NY.


B08  Longitudinal tracking of breast cancer patients over systemic disease progression. Manjusha Ghosh. University of Regensburg, Regensburg, Germany.

B09  NR2F1 limits dissemination and stem like features of early cancer mammary epithelial cells. M. Soledad Sosa. Icahn School of Medicine at Mount Sinai, New York, NY.

B10  Prevention of tumor dormancy in disseminated prostate cancer cells following androgen receptor inhibition by an inhibitor of phosphorylation of the translation initiation factor eIF4E. Khounish Sharma. VA Northern California Health Care System, Mather, CA.

B11  Assessing the phylogenetic relationship of early cancer spread in melanoma as basis for neoantigen identification for adjuvant immunotherapy. Sandra Huber. University of Regensburg, Regensburg, Germany.

B12  Metabolic targeting of chemoresistance perturbs clonal complexity in pancreatic cancer. Alessandro Carugo. University of Texas MD Anderson Cancer Center, Houston, TX.
B13 Metabolically adaptable cancer cells as a usable cell culture model of rapidly progressing poor-prognosis minimal residual disease in triple-negative breast cancer: Mechanistic insights and evaluation of a potential therapy. Balraj Singh. University of Texas MD Anderson Cancer Center, Houston, TX.

B14 Circulating tumor DNA analysis to examine dynamics of response and risk of acquired resistance to PD-1 blockade in long-term responders with NSCLC. Barzin Nabet. Stanford University, Stanford, CA.

B15 Mechanistic insights into bone marrow-resident cancer cell quiescence. Debasish Boral. Houston Methodist Research Institute, Houston, TX.


B17 Physical-confining matrix promotes dormancy of ER+ breast cancer cells in an estrogen-independent manner. Alptekin Aksan. University of Minnesota, Minneapolis, MN.

B18 A niche-based high-throughput screen to decipher mechanisms of survival in dormant disseminated tumor cells. Laura Pisarsky. Fred Hutchinson Cancer Research Center, Seattle, WA.

B19 HDAC inhibitors directly induce LIFR and stimulate expression of dormancy-associated genes in breast cancer cells. Miranda Sowder. Vanderbilt University, Nashville, TN.

B20 Genomic alterations regulating delayed recurrence of ER+ breast cancer. Parisa Imanirad. University of Texas MD Anderson Cancer Center, Houston, TX.

B21 AMPK activation via metformin enhances survival of residual clinically dormant ER+ breast tumor cells during estrogen deprivation therapy. Riley Hampsch. Department of Molecular & Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.


B23 AKT1low quiescent cancer cells in ductal carcinoma in situ of the breast. Sheheryar Kabraji. Dana-Farber Cancer Institute, Boston, MA.

B24 Investigating Dec2 as a biomarker of human dormant metastatic tumor cells in colorectal cancer. Stephanie Greco. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

B25 Identification and functional testing of NR2F1 agonists for dormancy induction and maintenance. Julio Aguirre-Ghiso. Icahn School of Medicine at Mount Sinai, New York, NY.


An immunocompetent and easily reproducible murine model for pancreatic cancer dormancy and recurrence. Vikas Dudeja. University of Miami, Miami, FL.

Tolerization against eGFP/ffLUC to enable consistent labeling of tumor cells in immune-competent mammary metastasis models. Candice Grzelak. Fred Hutchinson Cancer Research Center, Seattle, WA.

Development of a syngeneic mouse model of leukemia minimal residual disease: A new tool to study the involvement of the immune response in cancer cell persistence. Thierry Idziorek. INSEtM, Lille, France.

Clonal dynamics during tumor regression, residual disease, and recurrence. James Alvarez. Duke University School of Medicine, Durham, NC.

Molecular and vascular determinants of escape from dormancy in experimental glioma. Nadim Tawil. McGill University, Montreal, QC, Canada.

Evaluating the role of Mixed Lineage Kinase 3 in metastatic breast cancer. Kathleen Gallo. Michigan State University, East Lansing, MI.

Characterization of drug-tolerant G0-like, BRCA1-deficient breast cancer tumor cells. Kerstin Hahn. Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.


Breast cancer cutaneous metastases are associated to uMUC1 and sialyl Lewis x and to highly malignant primary tumors. Maria Croce. Center of Basic and Applied Immunological Research, Faculty of Medical Sciences, National University of La Plata, La Plata, Buenos Aires, Argentina.

The receptor tyrosine kinase AXL is required at multiple steps of the metastatic cascade during HER2-positive breast cancer progression. Marie-Anne Goyette. Montreal Clinical Research Institute (IRCM), Montreal, QC, Canada.

Epigenetic silencing of par-4 links residual cell survival and chemoresistance. Nathaniel Mabe. Duke University, Durham, NC.

CD44(+) oral squamous cell carcinoma cells induce initial angiogenesis in vivo. Nils Ludwig. Department of Pathology, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA.

Tumor-released exosomes induce tumor innervation: Contribution to tumor dormancy? Paola Vermeer. Sanford Research, Sioux Falls, SD.

Role of glycosaminoglycans in regulation of cancer cell dormancy utilizing novel in vitro and in vivo models of therapy-induced dormancy. Rio Boothello. Virginia Commonwealth University, Richmond, VA.
B42  **FGFR signaling facilitates recurrence of minimal residual disease post trastuzumab emtansine treatment in breast cancer.** Saeed Salehin Akhand. Purdue University, West Lafayette, IN.

B43  **A specialized post-transcriptional program in chemoresistant, quiescent cancer cells.** Shobha Vasudevan. MGH-Harvard Medical School, Boston, MA.

B44  **Potential of the water channel aquaporin 1 for detecting migrating tumor cells.** Stephanie Gros. Department of Pediatric Surgery, University Children's Hospital of Basel (UKBB), Basel, Basel Town, Switzerland.

B45  **Omics unveils a common calcium signature of tumor dormancy in two murine models of leukemia and melanoma.** Thierry Idziorek. UMR-S1172, Lille, France.